Please assess the completion status of the following clinical trial:

Trial Title: 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or non-pregnant, non-lactating female patients at least 18 years of age~* Diagnosis of moderate to severe AS with prior documented radiologic evidence (X-ray) fulfilling the Modified New York criteria for AS (1984)~* Patients should have been on NSAIDs with an inadequate response~* Patients who are regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose~* Patients who have been on an anti-TNFα agent (not more than one) must have experienced an inadequate response~Exclusion criteria:~* Chest X-ray with evidence of ongoing infectious or malignant process~* Patients with total ankylosis of the spine~* Patients previously treated with any biological immunomodulating agents except for those targeting TNFα~* Previous treatment with any cell-depleting therapies~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 10 mg/kg i.v. / 75 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Secukinumab 10 mg/kg i.v. / 150 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).